Comparing efficacy and safety between polymyxin B and colistin in the treatment of infections caused by carbapenem-resistant Gram-negative bacteria: a multicenter, randomized double-blind study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250206010

Enrollment

300

Registered

2025-02-06

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carbapenem-resistant Gram-negative bacterial infections efficacy and safety of the polymyxin B compared with colistin

Interventions

antibacterial agent,antibacterial agent

Active Comparator Drug,Experimental Drug

colistin,polymyxin b

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) The patients aged 18 years or above admitted to the hospital (2) The patients with laboratory-confirmed CRGNB

Exclusion criteria

Exclusion criteria: Patient allergic to polymyxins

Design outcomes

Primary

Measure	Time frame
efficacy 14 day after first dose of treatment all cause mortality in patient	—

Secondary

Measure	Time frame
safety 28 day after treatment adverse event	—

Countries

Thailand

Contacts

Public Contactchusana suankratay

Faculty of medicine , chulalongkorn university

csuankratay@gmail.com0818133755

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026